The Indianapolis-based insurer says the treatments are “investigational”—or still under clinical study—but a California woman claims the electrical stimulation is FDA-approved and supported by numerous studies.
Taltz rang up sales of $1.3 billion last year, an increase of 46%, making it Lilly’s fastest-growing drug. An estimated 137,000 patients have been treated with Taltz worldwide since its launch four years ago.
Philip and Martin Low’s latest venture, Eradivir, was incorporated in February to develop a treatment that would fight the influenza virus, but COVID-19 prompted a tweak to the business plan.
Around the world, more than 80 vaccine projects are under development by pharmaceutical companies and university research laboratories.
The not-for-profit and its health research are a testament to the idea that all innovation is related—even when the connection appears tenuous at first glance.
The company is one of many across the globe in a mad rush to develop radioligand therapies for cancer treatment—a field that’s expected to see explosive growth.
The Indiana Donor Network Organ and Tissue Recovery Center has re-tasked two operating rooms and an intensive care unit to recover major organs, such as the kidneys, heart and lungs.
Washington, D.C.-area-based Maximus is taking on a critical, massive assignment: helping health departments across Indiana contact people who have tested positive for COVID-19 to learn whom they might have exposed.
The IUPUI nursing professor is co-leading a study on health behaviors and health outcomes during the pandemic.
The design of the long-anticipated project was originally set to be unveiled by the end of 2018, but has been delayed several times—most recently this spring, as the pandemic began to sweep across the United States.
Hotel Tango hand sanitizer can now be found in Navy shipbuilding yards in Wisconsin, shoe retailers around the country, shipping companies that handle packages as an integral part of their business, as well as military ships and bases around the world.
The emerging health care field seeks to develop methods for replacing or reinvigorating damaged human organs, cells and tissues.
COVID-19 is not showing much mercy to seniors, or to people with high blood pressure, diabetes and other chronic conditions.
Across Indiana, local health departments have been scrambling to keep up with the job of tracking, one patient at a time, the spread of the virus that has already claimed the lives of more than 900 Hoosiers.
Gov. Eric Holcomb lifted the ban effective Monday, with some caveats, such as making sure that hospitals keep enough personnel and personal protective equipment on hand for COVID-19 patients.
The Fishers-based company’s latest acquisition realizes its transition from a niche repair firm for ultrasound components to a multinational imaging-machine supplier.
Dr. Cole Beeler knows people are itching to get back to business and resume their normal lives. But he warns employers and workers not to rush back to the old way of doing business, at least not all at once.
The two technologies are different, but the goal of both is to provide a result within 40 minutes. The researchers say they are working with manufacturers to develop the products, which they hope will retail for $5 or less.
For years, Indiana has struggled to get sufficient funds and equipment for its public health efforts. Now, it’s in the biggest health crisis in decades and is trying to make do with funding that ranks among the lowest in the nation.
Baricitinib, also known under the brand name Olumiant, is approved in more than 65 countries as a treatment for adults with moderately to severely active rheumatoid arthritis.
